Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2017 06:00 ET | Source: Dynavax Technologies

Dynavax to Present at the 2017 RBC Capital Markets Global Healthcare Conference

BERKELEY, CA--(Marketwired - February 16, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Michael Ostrach, Dynavax's senior vice president and chief financial officer,...
January 13, 2017 10:10 ET | Source: Bronstein, Gewirtz & Grossman, LLC

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dynavax Technologies Corporation (DVAX) and Lead Plaintiff Deadline: January 17, 2017

NEW YORK, Jan. 13, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Dynavax Technologies...
January 09, 2017 07:00 ET | Source: Dynavax Technologies

Dynavax to Present at J.P. Morgan 35th Annual Healthcare Conference

BERKELEY, CA--(Marketwired - January 09, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan...
January 05, 2017 12:35 ET | Source: Dynavax Technologies

Dynavax Restructures and Emphasizes Immuno-Oncology Program

BERKELEY, CA --(Marketwired - January 05, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage biopharmaceutical company, today announced that it is reshaping its strategy and...
January 02, 2017 08:00 ET | Source: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Dynavax Technologies Corporation of Class Action Lawsuit and Upcoming Deadline – DVAX

NEW YORK, Jan. 02, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NASDAQ:DVAX) and...
December 20, 2016 14:05 ET | Source: Brower Piven, A Professional Corporation

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Dynavax Technologies Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – DVAX

STEVENSON, Md., Dec. 20, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the...
December 16, 2016 11:15 ET | Source: The Law Offices of Vincent Wong

DVAX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dynavax Technologies Corporation and a Lead Plaintiff Deadline of January 17, 2017

NEW YORK, Dec. 16, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of...
December 13, 2016 10:10 ET | Source: Bronstein, Gewirtz & Grossman, LLC

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dynavax Technologies Corporation (DVAX) & Lead Plaintiff Deadline: January 17, 2017

NEW YORK, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Dynavax...
December 12, 2016 11:19 ET | Source: Levi & Korsinsky, LLP

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dynavax Technologies Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – DVAX

NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of...
December 05, 2016 07:00 ET | Source: Dynavax Technologies

Dynavax Presents Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, in Combination with Targeted Low-Dose Radiation, at ASH Annual Meeting

BERKELEY, CA--(Marketwired - December 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2, two-part clinical trial evaluating...